Gel for rash from EGFR inhibitor cancer therapy
Part of Skin clinical trials.
This trial tests a new gel (TAR-0520) for treating a bothersome, acne-like rash that often occurs on the face, scalp, or upper chest during cancer treatment with cetuximab or panitumumab. The goal is to see if it helps reduce the rash without affecting your cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have metastatic colorectal cancer and are being treated with cetuximab or panitumumab.
- You have a rash (folliculitis) caused by your EGFR inhibitor cancer treatment.
- You can apply the study gel yourself or have someone who can help.
- You are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cream called ATR04-484 to see if it can help with the painful rash that often appears on the face and chest during EGFR inhibitor cancer treatment. The cream is applied to the skin, with the goal of reducing redness, bumps, and discomfort.
This Phase 2 study tests a topical cream (HT-001) to treat skin rashes caused by EGFR inhibitors. It aims to see whether the cream is safe and can reduce rash symptoms and discomfort.
This study tests whether a topical tretinoin cream can prevent the skin rash often caused by anti-EGFR drugs like panitumumab or cetuximab. It is for people with advanced solid tumors who are about to start one of these treatments.
This trial tests whether a gel called TAR-0520 can prevent nerve damage (peripheral neuropathy) caused by common breast cancer drugs like paclitaxel or docetaxel. You'll apply the gel to your skin, and the study will see if it helps reduce numbness, tingling, or pain in your hands and feet.
This trial tests whether extra care for skin and infusion reactions can help people with EGFR-mutated advanced lung cancer better tolerate treatment with amivantamab-based therapies. It compares two approaches in three different patient groups.
This trial tests an oral drug called erlotinib (an EGFR inhibitor) in adults with certain genetic skin disorders. It aims to reduce symptoms of thickened, blistering or scaly skin. You may be able to join if you have a confirmed genetic form of these conditions and your skin is moderately affected.
Hear when a new EGFR Inhibitor-associated Rash trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.